Promising Phase 2 Trial Results: CTI-1601 Shows Increases in FXN Levels in Friedreich's Ataxia Participants, Says Larimar Therapeutics - MyChesCo
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical-stage biotechnology company, this week announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, …
MyChesCo
